Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas

Human Pathology

Volumn 54, Issue , 2016, Pages 17-24

  Menter, Thomas ^a,b   Bodmer Haecki, Andrea ^a   Dirnhofer, Stephan ^a   Tzankov, Alexandar ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

B cell lymphoma; Diagnostic marker; Hodgkin lymphoma; Immunohistochemistry; PDL1

Indexed keywords

CD20 ANTIGEN; CD68 ANTIGEN; CYCLIN D1; EBER PROTEIN; GCET1 PROTEIN; GRANZYME; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN; PROTEIN BCL 6; T CELL AND HISTIOCYTE RICH B CELL LYMPHOMA; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER DIAGNOSIS; CANCER PROGNOSIS; CLASSICAL HODGKIN LYMPHOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; GERMINAL CENTER; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MACROPHAGE; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PROTEIN EXPRESSION; REED STERNBERG CELL; T LYMPHOCYTE; TISSUE MICROARRAY; WALDENSTROEM MACROGLOBULINEMIA; BIOPSY; CHEMISTRY; DISEASE FREE SURVIVAL; EVALUATION STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; KAPLAN MEIER METHOD; LYMPHOMA, B-CELL; METABOLISM; PATHOLOGY; PREDICTIVE VALUE; TIME FACTOR;

ANTIGENS, CD; ANTIGENS, CD274; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOMARKERS, TUMOR; BIOPSY; DISEASE-FREE SURVIVAL; FORKHEAD TRANSCRIPTION FACTORS; GRANZYMES; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LYMPHOMA, B-CELL; MACROPHAGES; PREDICTIVE VALUE OF TESTS; T-LYMPHOCYTES; TIME FACTORS;

EID: 84969179537     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2016.03.005     Document Type: Article

References (41)

1. M.E. Keir, M.J. Butte, G.J. Freeman, and A.H. Sharpe PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 2008 677 704
2. H. Jin, R. Ahmed, and T. Okazaki Role of PD-1 in regulating T-cell immunity Curr Top Microbiol Immunol 350 2011 17 37
3. B.T. Fife, and K.E. Pauken The role of the PD-1 pathway in autoimmunity and peripheral tolerance Ann N Y Acad Sci 1217 2011 45 59
4. H. Nishimura, M. Nose, H. Hiai, N. Minato, and T. Honjo Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor Immunity 11 1999 141 151
5. J. Weber Immune checkpoint proteins: a new therapeutic paradigm for cancer - preclinical background: CTLA-4 and PD-1 blockade Semin Oncol 37 2010 430 439
6. S. Muenst, S.D. Soysal, A. Tzankov, and S. Hoeller The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy Expert Opin Ther Targets 19 2015 201 211
7. S. Muenst, S. Hoeller, S. Dirnhofer, and A. Tzankov Increased programmed death-1 + tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival Hum Pathol 40 2009 1715 1722
8. S. Muenst, S. Hoeller, N. Willi, S. Dirnhofera, and A. Tzankov Diagnostic and prognostic utility of PD-1 in B cell lymphomas Dis Markers 29 2010 47 53
9. A. Rosenwald, G. Wright, K. Leroy, and et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma J Exp Med 198 2003 851 862
10. C.B. Hutchinson, and E. Wang Primary mediastinal (thymic) large B-cell lymphoma: a short review with brief discussion of mediastinal gray zone lymphoma Arch Pathol Lab Med 135 2011 394 398
11. W. Yamamoto, N. Nakamura, N. Tomita, and et al. Clinicopathological analysis of mediastinal large B-cell lymphoma and classical Hodgkin lymphoma of the mediastinum Leuk Lymphoma 54 2013 967 972
12. C. Blank, T.F. Gajewski, and A. Mackensen Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy Cancer Immunol Immunother 54 2005 307 314
13. Y. Pico de Coaña, A. Choudhury, and R. Kiessling Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system Trends Mol Med 21 2015 482 491
14. C. Robert, G.V. Long, B. Brady, and et al. Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 2015 320 330
15. N.A. Rizvi, J. Mazières, D. Planchard, and et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Lancet Oncol 16 2015 257 265
16. S.M. Ansell, A.M. Lesokhin, I. Borrello, and et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma N Engl J Med 372 2015 311 319
17. C.D. Fankhauser, A. Curioni-Fontecedro, V. Allmann, and et al. Frequent PD-L1 expression in testicular germ cell tumors Br J Cancer 113 2015 411 413
18. C. Meier, S. Hoeller, C. Bourgau, and et al. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas Mod Pathol 22 2009 476 487
19. W. Sterlacci, S. Savic, T. Schmid, and et al. Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact Am J Clin Pathol 137 2012 946 956
20. B.J. Chen, B. Chapuy, J. Ouyang, and et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies Clin Cancer Res 19 2013 3462 3473
21. D.J. Andorsky, R.E. Yamada, J. Said, G.S. Pinkus, D.J. Betting, and J.M. Timmerman Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells Clin Cancer Res 17 2011 4232 4244
22. A. Traverse-Glehen, S. Pittaluga, P. Gaulard, and et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma Am J Surg Pathol 29 2005 1411 1421
23. A.S. Berghoff, G. Ricken, G. Widhalm, and et al. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL) Clin Neuropathol 33 2014 42 49
24. D. Rimm, K. Schalper, and L. Pusztai Unvalidated antibodies and misleading results Breast Cancer Res Treat 147 2014 457 458
25. V. Velcheti, K.A. Schalper, D.E. Carvajal, and et al. Programmed death ligand-1 expression in non-small cell lung cancer Lab Invest 94 2014 107 116
26. S. Joos, M.I. Otaño-Joos, S. Ziegler, and et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene Blood 87 1996 1571 1578
27. M.R. Green, S. Monti, S.J. Rodig, and et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma Blood 116 2010 3268 3277
28. M.R. Green, S. Rodig, P. Juszczynski, and et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy Clin Cancer Res 18 2012 1611 1618
29. M.A. Weniger, I. Melzner, C.K. Menz, and et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation Oncogene 25 2006 2679 2684
30. A. Navarro, T. Diaz, A. Martinez, and et al. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma Blood 114 2009 2945 2951
31. P.H. Wiernik, I.S. Lossos, J.M. Tuscano, and et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma J Clin Oncol 26 2008 4952 4957
32. G.S. Nowakowski, B. LaPlant, W.R. Macon, and et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study J Clin Oncol 33 2015 251 257
33. C.Y. Cheah, N.H. Fowler, and S.S. Neelapu Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma Curr Opin Oncol 27 2015 384 391
34. F. Bertucci, P. Finetti, E. Mamessier, and et al. PDL1 expression is an independent prognostic factor in localized GIST Oncoimmunology 4 2015 e1002729
35. R. Sabatier, P. Finetti, E. Mamessier, and et al. Prognostic and predictive value of PDL1 expression in breast cancer Oncotarget 6 2015 5449 5464
36. H. Ghebeh, E. Barhoush, A. Tulbah, N. Elkum, T. Al-Tweigeri, and S. Dermime FOXP3 + Tregs and B7-H1 +/PD-1 + T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy BMC Cancer 8 2008 57
37. R.P. Singh, A. La Cava, and B.H. Hahn pConsensus peptide induces tolerogenic CD8 + T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules J Immunol 180 2008 2069 2080
38. P. Greaves, A. Clear, R. Coutinho, and et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome J Clin Oncol 31 2013 256 262
39. A. Tzankov, M.S. Matter, and S. Dirnhofer Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma Pathobiology 77 2010 301 308
40. T. Menter, A. Gasser, D. Juskevicius, S. Dirnhofer, and A. Tzankov Diagnostic utility of the germinal center-associated markers GCET1, HGAL, and LMO2 in hematolymphoid neoplasms Appl Immunohistochem Mol Morphol 23 2015 491 498
41. J. Krugmann, A. Tzankov, A. Gschwendtner, and et al. Longer failure-free survival interval of Epstein-Barr virus-associated classical Hodgkin's lymphoma: a single-institution study Mod Pathol 16 2003 566 573